Invus is not a venture partnership. It describes itself as a global equity investment firm with an evergreen capital structure that invests in both private and public equity and is 'not forced to quickly realize investments in order to raise the next fund'. Its capital comes from a European family group, principally through the Artal vehicle. The firm organises itself by strategy and geography rather than by fund: Invus Private Equity teams in the United States, Europe and Asia, Invus Public Equity teams in the same three regions, and the sister fund Invus Opportunities. Its stated operating principles are that all key executives must be owners, that management runs the company rather than Invus, and that value is built on fundamental customer insights. It operates from New York, Paris and Hong Kong. The regulated adviser in the group is Invus Financial Advisors, LLC (SEC CRD 161603, file 801-73756), whose relying advisers are The Invus Group, LLC and Avicenna Management LP.
Over $10B (under management, stated on the firm's Who We Are page and homepage, checked 2026; Invus Opportunities is separately stated at more than $2B) AUM79/100 Power Score™1985 FoundedNew York, NY
Cava Group (NYSE: CAVA) listed on the New York Stock Exchange on 15 June 2023; Invus states that its affiliate Artal remained Cava's largest shareholder after the offering, so this is a public listing rather than a realised exit.
Raymond Debbane forms Invus, having previously been a manager at The Boston Consulting Group in Paris.
2007
Raymond Debbane, Christopher J. Sobecki and Philippe J. Amouyal all become directors of Lexicon Pharmaceuticals in August 2007, Amouyal as a designee of Invus, L.P. under a stockholders' agreement.
2012
Raymond Debbane becomes chairman of the Lexicon Pharmaceuticals board of directors in February 2012.
2015
Invus becomes a partner of Cava at Cava's Series A round, through its affiliate Artal International S.C.A.
2018
Philippe Amouyal and Benjamin Felt both join the Cava Group board of directors in November 2018.
2023
Cava Group lists on the New York Stock Exchange on 15 June 2023; Invus states that Artal remained Cava's largest shareholder following the offering.
2026
Artal Group S.A. files a Form 13F-HR for the quarter ended 30 June 2026 reporting two positions, Cava Group and Lexicon Pharmaceuticals, with a total value of $931,121,604, filed jointly with five other Artal entities.
2026
Invus Financial Advisors, LLC files a Form 13F-NT notice for the quarter ended 30 June 2026, reporting no holdings of its own.